• expand-bubble-1 drop-icon-bubble

    Inhibits evaporation1-6*

    Mimics key functions of natural meibum, promotes healing on the ocular surface, and may reduce friction.

    Learn More
  • expand-bubble-2 clock-icon-bubble

    Rapid and sustained relief1,5,6†

    Significant improvement in the signs and symptoms of dry eye disease (DED) as early as Day 15 with continued improvement through Day 57. 100% of patients had clinical signs of meibomian gland dysfunction (MGD) at enrollment.

    Learn More
  • expand-bubble-3 shield-icon-bubble

    Excellent tolerability1,5-7‡

    No serious ocular adverse events (AEs), low discontinuation rate due to AEs, and low rate of burning or stinging on instillation. The most common ocular adverse reaction was blurred vision, which was mostly mild and transient.

    Learn More
expand-bubble-1

Inhibits evaporation1-6*

Mimics key functions of natural meibum, promotes healing on the ocular surface, and may reduce friction.

LEARN MORE
expand-bubble-2

Rapid and sustained relief1,5,6†

Significant improvement in the signs and symptoms of dry eye disease (DED) as early as Day 15 with continued improvement through Day 57. 100% of patients had clinical signs of meibomian gland dysfunction (MGD) at enrollment.

LEARN MORE
expand-bubble-3

Excellent tolerability1,5-7‡

No serious ocular adverse events (AEs), low discontinuation rate due to AEs, and low rate of burning or stinging on instillation. The most common ocular adverse reaction was blurred vision, which was mostly mild and transient.

LEARN MORE
Tick Icon

American Academy of Ophthalmology Dry Eye Syndrome Preferred Practice Pattern® guidelines now include perfluorohexyloctane, the only ingredient in MIEBO1,8

DOWNLOAD GUIDELINES
 

MIEBO in action

*The exact mechanism of action for MIEBO in DED is not known.1

†Study design: Two 57-day, multicenter, double-masked, saline-controlled studies (GOBI and MOJAVE) were conducted in adults ≥18 years old with a self-reported history of DED in both eyes. Primary outcomes were change from baseline in total corneal fluorescein staining and change from baseline in eye dryness score at Day 57. Day 15 was the earliest time point at which signs and symptoms were evaluated in the trials. Day 57 (primary endpoints) was the last.1,5,6

‡Data were pooled from >1200 total patients from 2 pivotal clinical studies (GOBI and MOJAVE). Of the 614 patients who received MIEBO, there were no incidences of serious ocular AEs with MIEBO. Most AEs were considered mild. The discontinuation rate due to AEs for MIEBO was comparable to control (pooled: 0.2% vs 0.5%; GOBI: 0.3% vs 1.0%; MOJAVE: 0% vs 0%). 0.5% (pooled) of patients experienced instillation site pain AEs, such as burning or stinging (GOBI: 1.0%; MOJAVE: 0%). Blurred vision (pooled: 2.1%; GOBI: 3.0%; MOJAVE: 1.3%) and conjunctival redness (pooled: 0.8%; GOBI: 0%; MOJAVE: 1.3%) were reported in 1%-3% of individuals.1,5-7

UP NEXT Drivers of DED” inside droplet

UP NEXT

Drivers
of DED

arrow-circle-right
 
 
*Required fields.

By submitting your information, you consent to receive communications containing information and educational resources about MIEBO, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

*Required fields.

By submitting your information, you consent to receive communications containing information and educational resources about MIEBO, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for MIEBO.

References: 1. MIEBO. Prescribing Information. Bausch & Lomb, Inc. 2. Vittitow J, Kissling R, DeCory H, Borchman D. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98:100704. doi:10.1016/j.curtheres.2023.100704 3. Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397-1418. doi:10.1007/s40123-023-00669-1 4. Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154-161. doi:10.1089/jop.2019.0092 5. Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516-524. doi:10.1016/j.ophtha.2022.12.021 6. Sheppard JD, Kurata F, Epitropoulos AT, Krösser S, Vittitow JL; MOJAVE Study Group. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265-274. doi:10.1016/j.ajo.2023.03.008 7. Data on file. Bausch & Lomb, Inc. 8. Amescua G, Ahmad S, Cheung AY, et al; American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology. 2024;131(4):PP1-P49. doi:10.1016/j.ophtha.2023.12.041

Expand Expand Expand Expand

INDICATION AND IMPORTANT
SAFETY INFORMATION

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full prescribing Information for MIEBO.